PsilodexMedication × psilocybin
Your list , 0 items
General prescriptions
Brand names
Multaq
Reviewed 2026-10-04

Dronedarone

An antiarrhythmic, FDA-approved to reduce hospitalization for atrial fibrillation in people in normal rhythm with a history of paroxysmal or persistent atrial fibrillation.

psilodex.org/m/dronedarone · data v2026.10.05

Clinical contraindication
None listed
No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence
No psilocybin data
Half-life
13–19 h
Approximate, in adults. Source under Interaction below.
Named in state rules?
Not namedColorado Condition rules (3)
Not namedOregon
PendingNew Mexico
Cite asPsilodex, “Dronedarone”, v2026.10.05. psilodex.org/m/dronedarone

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for
  • Reduce risk of hospitalization for atrial fibrillation (paroxysmal or persistent AF, currently in sinus rhythm)
Sources [1]
Other safety

Boxed warning: doubles the risk of death in symptomatic heart failure with recent decompensation or NYHA Class IV heart failure, and increases death, stroke and heart failure in permanent atrial fibrillation.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

ND

It may slow how the body clears psilocybin by blocking enzymes. Also, it can affect heart rhythm.

Detail Dronedarone moderately inhibits CYP3A and CYP2D6, enzymes that metabolized psilocin in lab studies (Thomann 2024). So it may raise psilocin levels, though the body clears psilocin mainly by glucuronidation and conversion to 4-HIAA. There are no psilocybin data. It prolongs the QT interval (a heart-rhythm measure), and psilocybin briefly raises heart rate and blood pressure. Sources [1][2]

Human data with psilocybin
No psilocybin data; based on how it works and its label
Half-life
13–19 h (FDA label, checked 2026-10-04)
Evidence types on this record
No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

2 listed · counted on reports
Liver injury
The label or source warns of liver injury, from raised liver enzymes to liver failure. Liver disease also affects how the body clears psilocin. Sources [1]
QT-prolonging
Lengthens the QT interval on an ECG, a measure of the heart’s electrical recovery between beats. A long QT raises the risk of a dangerous heart rhythm, more so with other QT-prolonging drugs or low potassium or magnesium. Sources [1]

03 State rules

Plain-language summary · official text governs
CO4 CCR 755-1
Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04
OROAR 333-333
Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04
NM7.35.3 NMAC (proposed)
Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

  • Cardiovascular disease likely
    • CO 2.5(A)(2) · Clinical Facilitator licensees
    • CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
    • CO 6.16(F)(1) · All licensees

05 Sources

2
  1. MULTAQ (dronedarone) tablets (Sanofi) · FDA label (DailyMed) — revised 2025-06 | QT-prolonging: 5.8 QT Interval Prolongation "MULTAQ is associated with concentration-dependent QTcF interval prolongation" | Liver injury: 5.5 Liver Injury "Hepatocellular liver injury, including acute liver failure requiring transplant, has been reported in patients treated with MULTAQ in the postmarketing setting." | "Dronedarone is metabolized primarily by CYP3A and is a moderate inhibitor of CYP3A and CYP2D6." | "The elimination half-life of dronedarone ranges from 13 to 19 hours."
  2. Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689. — Abstract: "recombinant CYP2D6 and CYP3A4 enzymes metabolized nearly 100% and 40% of psilocin, respectively." "MAO-A transformed psilocin into minimal amounts of 4-HIAA and 4-HTP." "In conclusion, MAO-A, CYP2D6, and CYP3A4 are involved in psilocin's metabolism." Introduction: "Around 33% of a psilocybin dose is renally excreted as 4-HIAA."

Record history

  • v2026.10.02First published.
  • 2026-10-04Last reviewed against its sources.

Report an error in this record →

Before you startTerms 2026-10-01

What Psilodex is, and isn't.

  1. 01Psilodex summarizes published evidence and public state rules. It does not decide whether you can safely use psilocybin or take part in services, and it is not medical advice.
  2. 02Psilodex presents information only. Do not stop or change a medication without talking with the prescriber. Bring the report to them.
  3. 03Your searches and list stay in this browser and are not sent to us. Opening a medication's page is an ordinary web request, so our hosting providers see which page was opened. What we can and can't see.

In an emergency, call 911. For a mental health crisis, call or text 988. Full terms and privacy.